In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Ilex and Lilly collaborate on oncology compound

Executive Summary

Ilex Oncology (cancer therapeutics) and Lilly will collaborate to develop Lilly compound, LY295501 (diarysulfonylurea), which in Phase I clinical trials has shown promise as an antitumor agent relative to lung, ovarian, pancreatic, and colon cancers.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Equity
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies

UsernamePublicRestriction

Register